XBLA.MU
Bangkok Life Assurance PCL
MunichEUREQUITY
DELAYED
Last price
0.68
▲ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.68
Prev close
0.68
Day high
0.00
Day low
0.00
Volume
0
Market cap
—
P/E (TTM)
—
52W range
0.00 – 0.56
Day trading desk
Gap from prior close
—
—
VWAP
—
—
Relative volume
—
—
Session range
—
0.68 – 0.68
Position in range
—
—
ATR (14D)
—
Daily true range
Prior day high
—
PDH
Prior day low
—
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Shares traded
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on XBLA.MU open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $25.67B | $24.12B | $44.89B | $48.07B | +6.4% |
| Operating revenue | $25.67B | $24.12B | $44.89B | $48.07B | +6.4% |
| Selling, general & admin | $279.58M | $292.10M | $962.52M | $908.50M | -4.3% |
| Net interest income | -$12.54M | -$20.35M | — | — | +38.4% |
| Pre-tax income | $8.04B | $5.58B | $2.99B | $3.78B | +44.2% |
| Tax provision | $1.07B | $943.79M | $443.19M | $567.69M | +13.6% |
| Net income | $6.97B | $4.63B | $2.55B | $3.21B | +50.4% |
| Net income to common | $6.97B | $4.63B | $2.55B | $3.21B | +50.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.68B | $10.52B | $16.08B | $12.68B | — | -36.5% |
| Cash & short-term investments | $294.53B | $294.12B | $16.08B | $120.64B | — | +0.1% |
| Accounts receivable | — | $2.37B | $2.63B | $2.61B | $2.74B | — |
| Property, plant & equipment | $1.86B | $1.92B | $2.00B | $2.19B | — | -3.4% |
| Goodwill & intangibles | $123.10M | $131.55M | $126.10M | $141.12M | — | -6.4% |
| Total assets | $315.97B | $315.34B | $317.76B | $342.61B | — | +0.2% |
| Total liabilities | $260.78B | $267.28B | $273.73B | $297.83B | — | -2.4% |
| Retained earnings | $43.25B | $39.69B | $35.75B | $35.67B | — | +9.0% |
| Shareholder equity | $55.20B | $48.06B | $44.03B | $44.78B | — | +14.8% |
| Net tangible assets | $55.07B | $47.93B | $43.90B | $44.64B | — | +14.9% |
| Shares issued | 1.71B | 1.71B | 1.71B | 1.71B | — | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Capital expenditure | -$87.88M | -$33.34M | -$33.74M | -$57.00M | -163.6% |
| Investing cash flow | -$87.88M | -$33.34M | -$33.74M | -$57.00M | -163.6% |
| Dividends paid | -$1.46B | -$679.87M | -$953.78M | -$1.50B | -114.3% |
| Financing cash flow | -$1.46B | -$679.87M | -$953.78M | -$1.50B | -114.3% |
| Free cash flow | -$2.38B | -$4.88B | $4.36B | $6.54B | +51.2% |
| End cash position | $6.68B | $10.52B | $16.08B | $12.68B | -36.5% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $6.10B | $5.81B | $7.24B | $4.86B | $5.70B | — | +5.1% |
| Operating revenue | $6.10B | $5.81B | $7.24B | $4.86B | $5.70B | — | +5.1% |
| Selling, general & admin | — | — | — | — | — | $258.32M | — |
| Net interest income | -$1.73M | -$7.21M | -$2.24M | -$3.10M | $0 | — | +76.0% |
| Pre-tax income | $1.91B | $1.67B | $2.77B | $2.47B | $1.20B | — | +14.1% |
| Tax provision | $304.45M | $329.51M | $464.46M | $338.22M | -$46.71M | — | -7.6% |
| Net income | $1.61B | $1.34B | $2.31B | $2.13B | $1.25B | — | +19.4% |
| Net income to common | $1.61B | $1.34B | $2.31B | $2.13B | $1.25B | — | +19.4% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.75B | $6.68B | $8.58B | $8.19B | $6.79B | — | -58.9% |
| Cash & short-term investments | $278.15B | $294.53B | $298.28B | $297.36B | $288.77B | — | -5.6% |
| Accounts receivable | — | — | — | — | — | $2.37B | — |
| Property, plant & equipment | $1.84B | $1.86B | $1.89B | $1.91B | $1.92B | — | -0.8% |
| Goodwill & intangibles | $116.84M | $123.10M | $127.39M | $127.71M | $128.27M | — | -5.1% |
| Total assets | $300.70B | $315.97B | $325.49B | $322.58B | $314.17B | — | -4.8% |
| Total liabilities | $247.64B | $260.78B | $270.08B | $274.25B | $266.42B | — | -5.0% |
| Retained earnings | $44.86B | $43.25B | $40.74B | $39.29B | $38.46B | — | +3.7% |
| Shareholder equity | $53.06B | $55.20B | $55.41B | $48.33B | $47.75B | — | -3.9% |
| Net tangible assets | $52.94B | $55.07B | $55.28B | $48.20B | $47.62B | — | -3.9% |
| Shares issued | 1.71B | 1.71B | 1.71B | 1.71B | 1.71B | — | 0.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Capital expenditure | — | -$69.30M | — | -$16.59M | -$24.75M | -$9.28M | — |
| Investing cash flow | $7.61M | -$69.30M | $22.75M | -$16.59M | -$24.75M | — | +111.0% |
| Dividends paid | — | -$644.02M | -$1.00K | — | — | -$339.37M | — |
| Financing cash flow | — | -$644.02M | -$1.00K | — | — | -$339.37M | — |
| Free cash flow | -$3.94B | -$1.26B | $389.74M | $2.22B | -$3.74B | — | -213.8% |
| End cash position | $2.75B | $6.68B | $8.58B | $8.19B | $6.79B | — | -58.9% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
—
—
SMA 20
—
—
SMA 50
—
—
SMA 100
—
—
SMA 200
—
—
EMA 12
—
—
EMA 26
—
—
EMA 50
—
—
RSI (14)
—
—
MACD (12,26,9)
—
Hist —
ATR (14)
—
—
Realised vol 30D
—
Annualised
Bollinger upper
—
20, 2σ
Bollinger lower
—
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
—
—
Correlation to SPY
—
—
Realised vol 30D
—
Annualised
Market vol 1Y
—
SPY, annualised
Max drawdown 1Y
—
Peak to trough
Max drawdown 5Y
—
Peak to trough
ATR 14
—
Average true range
Beta (reported)
—
5Y monthly, from filing
Headlines
Kyle Bachus of Bachus & Schanker Named 2026 Best Personal Injury Lawyer by Law Week Colorado
ACCESS Newswire · 10m ago
Trump makes final pitch for Sen. Darline Graham before South Carolina runoff
USA TODAY · 13m ago
NewPeak Metals to showcase Las Opeñas drilling results in investor webinar
Proactive · 15m ago
South Korea's SK Hynix union members reject wage agreement in vote
Reuters · 17m ago
Federer looks forward to brief return to Arthur Ashe stadium
AFP · 19m ago
Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
PR Newswire · 20m ago
Macy’s has a $265 Calvin Klein puffer coat with 'a flattering fit' for 85% off
TheStreet · 20m ago
XPeng (XPEV) Q2 2026 Earnings Call Transcript
Motley Fool · 21m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.